ASND
Ascendis Pharma A/S
NASDAQ · Healthcare · Biotechnology · DK
$229.95
+2.09%Oct 6, 2026, 13:15 UTC
Ascendis Pharma announced that advances in its hypoparathyroidism and achondroplasia programs, including 5-year combined skeletal data for TransCon PTH (palopegteriparatide), will be presented at ASBMR 2026 in Boston on October 9-12, 2026.
Source:Sep 30, 2026, 20:24 UTC
BioMarin Pharmaceutical granted Ascendis Pharma a non-exclusive worldwide license to certain patents for products including TransCon CNP, navepegritide, and Yuviwel, with Ascendis paying 20% royalties on US net sales and 18% in the EU, Brazil, and South Korea until May 2030, and the parties agreed to dismiss all pending litigation with prejudice.
Sep 14, 2026, 22:00 UTC
Ascendis Pharma will regain all rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, and plans to initiate multiple programs in those areas including obesity.
Source:Sep 14, 2026, 22:00 UTC
Ascendis Pharma A/S announced that its Board of Directors authorized a share repurchase program of up to $400 million of its ordinary shares.
Source:Aug 31, 2026, 11:05 UTC
BioMarin Pharmaceutical signed a binding term sheet with Ascendis Pharma for a global settlement and license agreement, granting Ascendis a non-exclusive, worldwide, royalty-bearing license to certain BioMarin patents for products including TransCon CNP, navepegritide, or Yuviwel, with all pending litigation to be dismissed with prejudice.
Source:Aug 13, 2026, 11:30 UTC
Ascendis Pharma reported its second quarter 2026 financial results, with product revenue of €315 million, up 105% year-over-year.